REG - Oxford Cannabinoid - Director/PDMR Shareholding

Oxford Cannabinoid Technologies HoldingsAnnouncement

15/12/2022 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221215:nRSO8861Ja&default-theme=true

RNS Number : 8861J  Oxford Cannabinoid Tech.Holdings  15 December 2022

Oxford Cannabinoid Technologies Holdings plc

Director Dealings

Oxford Cannabinoid Technologies Holdings plc ("the Company"), announces that
it has been informed today that Clarissa Sowemimo-Coker, the Interim Chief
Executive Officer has today purchased ordinary shares of £0.01 in the Company
("Ordinary Shares").

 Director                 Total number of Ordinary Shares purchased  Price per Ordinary Share  Number of Ordinary Shares held following the purchase
 Clarissa Sowemimo-Coker  500,000                                    £0.00615                  1,189,594

                          500,000                                    £0.00625

 

The PDMR form is set out below.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this
announcement.

 

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Clarissa Sowemimo-Coker (Interim CEO)         clarissa@oxcantech.com

 Cairn Financial Advisers LLP

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited

 Kamran Hussain                                +44 (0)20 3026 0320

 Richard Hutchison

 finnCap Ltd

 Geoff Nash/Fergus Sullivan                    +44 (0) 20 7220 0500

 Nigel Birks (ECM)

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann/Nick Rome                           +44 (0)7768 807631

                                               oxcantech@walbrookpr.com (mailto:oxcantech@walbrookpr.com)

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc is the holding company of Oxford
Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group
developing prescription cannabinoid medicines for approval by key medicines
regulatory agencies worldwide and targeting the U$ multi-billion pain market.
Cannabinoids are compounds found in the cannabis plant that have been shown to
have a range of therapeutic effects on the body, including pain relief. The
Group has a clearly defined path to commercialisation, revenues and growth.
The Group is developing drug candidates through clinical trials to gain
regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to
prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst
ensuring market exclusivity around all its key activities. The Group's lead
compound, OCT461201, is a highly potent and selective CB2 agonist and is being
developed by OCTP in a solid oral dosage form. OCTP is conducting pre-clinical
testing and development with a clinical trial scheduled for Q1 2023. The
Group's product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of rare
diseases and includes chemically modified phytocannabinoids with improved
drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial
partners.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Clarissa Sowemimo-Coker
 2   Reason for notification

 a.  Position/Status                                              Interim Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Oxford Cannabinoid Technologies Holdings plc
 b.  LEI

                                                                  2138005SRWT4998BCE35

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument

Identification Code                                         Ordinary shares of £0.01 each

                                                                  GB00BMVMRB86
 b.  Nature of the transaction                                    Acquisition of ordinary shares of £0.01 each
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     £0.00625                                                                 500,000
                                                                              £0.00615    500,000

 d.  Aggregated information

     - Aggregated Volume                                          1,000,000

     - Price                                                      £0.0062
 e.  Date of the transaction                                      15(th) December 2022
 f.  Place of the transaction                                     London, UK

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSSFLLELIF